(:BLCM)

Mar 14, 2023 04:30 pm ET
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in...
Feb 16, 2023 07:30 am ET
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers...
Jan 31, 2023 06:43 pm ET
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not 45,000, as previously stated. The corrected release follows: Bellicum Pharmaceuticals, Inc....
Jan 31, 2023 04:36 pm ET
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The...
Jan 19, 2023 07:30 am ET
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T® product...
Dec 11, 2022 10:00 am ET
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC...
Nov 10, 2022 04:05 pm ET
Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2022 and provided an operational update. “We are encouraged by...
Oct 31, 2022 05:49 pm ET
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The...
Oct 04, 2022 07:30 am ET
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held...
Oct 03, 2022 04:05 pm ET
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 70,000 stock options. The...
Sep 01, 2022 07:30 am ET
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment...
Aug 11, 2022 04:02 pm ET
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2022 and provided an operational update. “We have continued...
Jul 01, 2022 07:30 am ET
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 2 new employees consisting of an aggregate of 135,000 stock options. The...
May 12, 2022 04:05 pm ET
Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2022 and provided an operational update. “I am pleased with the...
May 02, 2022 07:30 am ET
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 3 new employees consisting of an aggregate of 33,000 stock options. The...
Mar 24, 2022 04:05 pm ET
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the fourth quarter and full year 2021 and provided an operational update....
Jan 26, 2022 04:05 pm ET
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the B. Riley Securities 2022 Virtual Oncology...
Dec 13, 2021 04:05 pm ET
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock...
Dec 06, 2021 07:30 am ET
Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced positive interim data from its ongoing Phase 1/2 GoCAR-T clinical trials, including a confirmed partial...
Nov 04, 2021 04:05 pm ET
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2021 and provided an operational update. “In the third quarter,...
Sep 03, 2021 07:30 am ET
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 23rd Annual Global Investment...
Sep 01, 2021 08:32 am ET
Thinking about buying stock in Skillz, Rigel Pharmaceuticals, Dynavax Technologies, Bellicum Pharmaceuticals, or Baudax Bio?
NEW YORK, Sept. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SKLZ, RIGL, DVAX, BLCM, and BXRX.
Sep 01, 2021 07:30 am ET
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas MD Anderson Cancer Center today announced a global option and license agreement covering...
Aug 12, 2021 04:05 pm ET
Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2021 and provided an operational update. “In the second...
Jul 26, 2021 05:25 pm ET
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity inducement grant to one new employee consisting of an aggregate of 15,000 stock options. The...
Jun 28, 2021 07:30 am ET
Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered into a license agreement with the University of North Carolina Lineberger Comprehensive...
May 17, 2021 07:30 am ET
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2021 and provided an operational update. “In the first...
Mar 30, 2021 04:05 pm ET
Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the fourth quarter and full year 2020 and provided an operational update. “In...
Mar 23, 2021 04:05 pm ET
Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the fourth quarter and full year 2020 after the close of U.S....
Mar 04, 2021 07:30 am ET
Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication of a case report using the company’s CaspaCIDe (inducible caspase-9, or iC9) safety...
Feb 08, 2021 07:30 am ET
Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin
MIAMI, Feb. 8, 2021 /PRNewswire/ -- Ponce Therapeutics, Inc. ("Ponce"), a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, has now become operational with the launching of its first R & D program, targeting aging-associated skin disorders. The Company has secured laboratory space in Houston, TX, and has hired its first scientists for executing their R & D plan targeting the elimination of p16-expressing cells in the skin. The cell proliferation inhibitor, p16, is highly expressed in both senescent cells and in in si
Jan 28, 2021 04:05 pm ET
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on patient enrollment and...
Dec 10, 2020 07:30 am ET
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients...
Dec 07, 2020 07:30 am ET
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that a clinical hold has been...
Nov 05, 2020 04:05 pm ET
Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2020 and provided an operational update. “Bellicum recently took...
Nov 03, 2020 08:25 pm ET
Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of its underwritten offering of 1,040,000 shares of common stock, pre-funded warrants to...
Oct 29, 2020 05:16 pm ET
Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of...
Oct 29, 2020 05:15 pm ET
Bellicum Announces Interim BPX-601 Data and Corporate Restructuring
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data from its BPX-601 dose-escalation clinical trial in patients with relapsed/refractory...
Sep 30, 2020 04:06 pm ET
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to one new employee consisting of an aggregate of 1,110 stock options. The...
Sep 28, 2020 07:30 am ET
Bellicum to Participate in Two Upcoming Virtual Conferences
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual conferences. Conference Details: Jefferies...
Sep 02, 2020 07:30 am ET
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor conferences. Conference Details:...
Aug 31, 2020 04:07 pm ET
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to three new employees consisting of an aggregate of 13,680 stock options. The...
Aug 06, 2020 04:05 pm ET
Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2020 and provided an operational update. “Bellicum continued to...
Jul 31, 2020 04:08 pm ET
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to two new employees consisting of an aggregate of 3,520 stock options. The...
Jul 30, 2020 04:05 pm ET
Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the second quarter 2020 after the close of U.S. markets on Thursday,...
Jun 15, 2020 07:30 am ET
Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application...
Jun 03, 2020 09:00 am ET
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9th-12th, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below along with webcasting links to view presentations.
May 29, 2020 04:06 pm ET
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to one new employee consisting of an aggregate of 16,820 stock options. The...
May 27, 2020 04:05 pm ET
Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication of preclinical data from its GoCAR-NK™ Cell Program in the digital edition of Blood...
May 27, 2020 07:30 am ET
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor conferences. Conference Details:...
May 07, 2020 04:05 pm ET
Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update  
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2020 and provided an operational update. “Bellicum entered the...
Apr 30, 2020 04:09 pm ET
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to one new employee consisting of an aggregate of 15,000 stock options. The...
Apr 15, 2020 07:30 am ET
Bellicum Completes Sale of Houston Facility
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced closing of the sale of its Houston facility to The University of Texas MD Anderson Cancer Center at a...
Mar 12, 2020 04:05 pm ET
Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the fourth quarter and full year 2019 and provided an operational update. “Bellicum...
Mar 05, 2020 07:30 am ET
Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the fourth quarter and full year 2019 after the close of U.S....
Feb 28, 2020 04:08 pm ET
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to one new employee consisting of an aggregate of 15,000 stock options. The...
Feb 05, 2020 12:45 pm ET
Bellicum Announces Reverse Stock Split
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the Company effected a reverse stock split of its issued and...
Jan 31, 2020 04:05 pm ET
Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Compensation Committee of the Board of Directors has...
Jan 24, 2020 07:30 am ET
Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1 translational results for BPX-601 at the American Society of Clinical Oncology...
Jan 21, 2020 07:30 am ET
Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered into an asset purchase agreement under which The University of Texas MD Anderson Cancer...
Jan 16, 2020 07:30 am ET
Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on new Phase 1 translational results for BPX-601, its lead GoCAR-T product candidate,...
Dec 11, 2019 07:30 am ET
Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The University of Texas MD Anderson Cancer Center exercised its option to license Bellicum’s...
Nov 22, 2019 10:50 pm ET
BELLICUM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Bellicum Pharmaceuticals, Inc. - BLCM
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Bellicum Pharmaceuticals, Inc. (NasdaqGM: BLCM).
Nov 08, 2019 07:00 am ET
Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented a poster showing preclinical data from its natural killer (NK) cell chimeric antigen receptor (CAR)...
Nov 06, 2019 04:15 pm ET
Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2019 and provided an operational update. “Bellicum made...
Oct 31, 2019 04:05 pm ET
Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract for a preclinical investigation from its natural killer cell chimeric antigen receptor...
Oct 30, 2019 07:30 am ET
Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the third quarter of 2019 after the close of U.S. markets on...
Sep 30, 2019 04:07 pm ET
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced an equity inducement grant to one new employee consisting of an...
Aug 30, 2019 04:08 pm ET
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced an equity inducement grant to one new employee consisting of an...
Aug 28, 2019 04:05 pm ET
Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will participate in three upcoming healthcare...
Aug 21, 2019 04:05 pm ET
Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public...
Aug 16, 2019 08:30 am ET
Bellicum Pharmaceuticals Announces Pricing of Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public offering of 575,000 shares of...
Aug 15, 2019 05:37 pm ET
Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it is offering to sell, subject to market and other...
Aug 05, 2019 04:15 pm ET
Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the second quarter 2019 and provided an...
Jul 08, 2019 08:00 am ET
Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the primary endpoint of event free survival at 180 days in its...
Jun 01, 2019 09:00 am ET
Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced updated safety and activity data for BPX-601 from a Phase1/2 study...
May 31, 2019 07:00 pm ET
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) and Encourages Bellicum Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM). Click here to participate in the action. On February 6, 2018 a complaint was filed alleging...
May 31, 2019 04:14 pm ET
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced equity inducement grants to four new employees consisting of an...
May 29, 2019 04:05 pm ET
Bellicum Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a...
May 20, 2019 08:38 am ET
(BLCM) Alert: Johnson Fistel, LLP Announces Investigation of Bellicum Pharmaceuticals, Inc.; Long Term Investors Encouraged to Contact Firm
SAN DIEGO, May 20, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) ("Bellicum")  and certain of its officers.
May 15, 2019 04:05 pm ET
Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that its abstract for BPX-601 has been accepted for poster...
May 07, 2019 07:30 am ET
Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter 2019 and provided an...
Mar 27, 2019 07:30 am ET
Bellicum Pharmaceuticals to Participate in Jefferies 6th Annual IO Cell Therapy Summit
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced participation in the Jefferies 6th Annual IO Cell Therapy Summit...
Mar 12, 2019 04:01 pm ET
Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2018
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the fourth quarter and full year ended December...
Mar 05, 2019 07:00 am ET
Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call and Webcast on Tuesday, March 12, 2019
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on...
Jan 30, 2019 07:30 am ET
Report: Developing Opportunities within Waste Connections, Performance Food Group, HealthEquity, PS Business Parks, Adverum Biotechnologies, and Bellicum Pharmaceuticals — Future Expectations, Project
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Waste Connections, Inc. (NYSE:WCN), Performance Food Group Company...
Dec 20, 2018 07:00 am ET
Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Judith Klimovsky, M.D., to its board of...
Dec 14, 2018 07:00 am ET
Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported safety and promising activity of BPX-601 in Part 1 of a Phase 1/2...
Dec 13, 2018 07:00 am ET
Bellicum Pharmaceuticals Appoints Atabak Mokari as Chief Financial Officer
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Atabak Mokari as Chief Financial Officer,...
Dec 02, 2018 10:30 am ET
Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced additional follow-up results from a subset of children with...
Dec 01, 2018 02:00 pm ET
Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced interim results from two multicenter trials of patients treated with...
Dec 01, 2018 12:00 pm ET
Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced late interim results from its BP-004 European registration trial,...
Nov 28, 2018 08:30 am ET
Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), NetEase, Inc....
Nov 27, 2018 07:00 am ET
Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it will host an analyst and investor luncheon event and webcast...
Nov 07, 2018 07:00 am ET
Bellicum Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a...
Nov 06, 2018 04:01 pm ET
Bellicum Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the third quarter ended September 30, 2018, and...
Nov 01, 2018 09:01 am ET
Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported that eight abstracts–including two oral presentations–on the...
Oct 17, 2018 08:30 am ET
Report: Exploring Fundamental Drivers Behind Bellicum Pharmaceuticals, Social Reality, Exelixis, Edgewell Personal Care, Cronos Group, and Acacia Communications — New Horizons, Emerging Trends, and Up
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), Social Reality Inc....
Aug 29, 2018 07:00 am ET
Bellicum Pharmaceuticals to Participate in Two Healthcare Investor Conferences in September
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will participate in two upcoming healthcare...
Aug 23, 2018 08:15 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Qurate Retail Group, Bellicum Pharmaceuticals, CannTrust, Iconix Brand Group, Maxwell Technologies, and AZUL SA — New Research Empha
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Qurate Retail Group, Inc. (NASDAQ:QRTEA), Bellicum Pharmaceuticals, Inc....
Aug 07, 2018 04:05 pm ET
Bellicum Pharmaceuticals Reports Second Quarter 2018 Financial Results
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the second quarter ended June 30, 2018, and...
Aug 06, 2018 07:00 am ET
Bellicum Pharmaceuticals Appoints Dr. Thierry Darcis as General Manager of Europe to Lead the Anticipated Launch of BPX-501
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Thierry Darcis, M.D., M.B.A. as General Manager...
Jul 31, 2018 07:00 am ET
Bellicum Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on...
Jul 16, 2018 04:25 pm ET
Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Alan Musso, Chief Financial Officer, will be leaving the...
Jun 15, 2018 07:45 am ET
Analysis: Positioning to Benefit within Uranium Energy, Bellicum Pharmaceuticals, Tutor Perini, Maiden, Hill-Rom, and BioDelivery Sciences International — Research Highlights Growth, Revenue, and Cons
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Uranium Energy Corp. (NYSE:UEC), Bellicum Pharmaceuticals, Inc....
May 30, 2018 07:00 am ET
Bellicum Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a...
May 29, 2018 07:00 am ET
Bellicum Pharmaceuticals Appoints Shane Ward as General Counsel
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Shane M. Ward as General Counsel and Corporate...
May 17, 2018 09:20 am ET
Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that two abstracts on its lead product candidate BPX-501 have been...
May 15, 2018 07:00 am ET
Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that data from preclinical studies of its HER2-targeted CAR-T cell...
May 08, 2018 04:01 pm ET
Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter ended March 31, 2018, and...
Apr 20, 2018 04:05 pm ET
Bellicum Pharmaceuticals Announces Closing of Public Offering
HOUSTON, April 20, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced...
Apr 17, 2018 06:26 pm ET
Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
HOUSTON, April 17, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public...
Apr 16, 2018 04:42 pm ET
Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
HOUSTON, April 16, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it has commenced an underwritten...
Apr 11, 2018 04:17 pm ET
Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501
HOUSTON, April 11, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the U.S. Food and Drug Administration has lifted the clinical...
Apr 01, 2018 06:00 am ET
FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bellicum Phar
STEVENSON, Md., April 01, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District...
Mar 26, 2018 05:31 pm ET
BELLICUM LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Bellicum Pharmaceuticals, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM) of the April 9, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Mar 21, 2018 04:03 pm ET
BLCM NOTICE: Rosen Law Firm Announces Filing of Class Action Against Bellicum Pharmaceuticals, Inc. - BLCM
NEW YORK, March 21, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a suit has been filed on behalf of purchasers of the securities of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) from May 8, 2017 through January 30, 2018, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Bellicum investors under the federal securities laws.
Mar 17, 2018 08:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bellicum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – BLCM
Pomerantz LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ: BLCM) and certain of its officers. The class action, filed in United States District Court, for the Southern District of Texas, and docketed under 18-cv-00338, is on behalf of a class consisting of investors who purchased or otherwise acquired Bellicum securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
Mar 16, 2018 03:49 pm ET
BELLICUM LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Bellicum Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, March 16, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ: BLCM) of the April 9, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Mar 14, 2018 01:47 pm ET
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Bellicum Pharmaceuticals, Inc.
Robbins Geller Rudman & Dowd LLP (“Robbins Geller”) (http://
Mar 13, 2018 04:01 pm ET
Mar 13, 2018 02:14 pm ET
DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Bellicum Pharmaceutical
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Texas on behalf of purchasers of Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”) securities during the period between May 8, 2017 and January 30, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 9, 2018 to seek appointment as lead plaintiff.
Mar 13, 2018 07:00 am ET
Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501
Company also reports encouraging disease-free survival and overall survival rates in pediatric patients with primary immunodeficiencies
Mar 11, 2018 08:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Bellicum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – BLCM
Pomerantz LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ: BLCM) and certain of its officers. The class action, filed in United States District Court, for the Southern District of Texas, and docketed under 18-cv-00338, is on behalf of a class consisting of investors who purchased or otherwise acquired Bellicum securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
Mar 09, 2018 04:14 pm ET
BELLICUM LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors who Suffered Losses Exceeding $50,000 in Bellicum Pharmaceuticals, Inc. to Contact the Firm
NEW YORK, March 09, 2018 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM) of the April 9, 2018 deadline to seek the...
Mar 06, 2018 07:00 am ET
Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018
HOUSTON, March 06, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast...
Mar 05, 2018 12:54 pm ET
EQUITY NOTICE: Rosen Law Firm Announces Filing of Class Action Against Bellicum Pharmaceuticals, Inc. – BLCM
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces that a lawsuit has been filed on behalf of purchasers of the securities of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) from May...
Mar 05, 2018 10:00 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) and Lead Plaintiff Deadline – April 9, 2018
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM) and certain of its...
Mar 02, 2018 11:25 pm ET
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) To Contact Brower Piven Before The Lead Plain
STEVENSON, Md., March 02, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District...
Mar 01, 2018 07:14 am ET
Bellicum (BLCM) Alert: Johnson Fistel Announces Filing of Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.; Encourages Investors to Contact the Firm
SAN DIEGO, March 1, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) ("Bellicum") on behalf of all purchasers of common stock during the period between May 8, 2017 and January 30, 2018, inclusive (the "Class Period"). Bellicum focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders.
Feb 27, 2018 06:02 pm ET
BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Bellicum Pharmaceuticals, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM).
Feb 24, 2018 08:10 am ET
Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers – BLCM
NEW YORK, Feb. 24, 2018 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM) and certain of its officers.   The class action, filed in...
Feb 23, 2018 11:05 am ET
BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM).
Feb 23, 2018 07:00 am ET
Bellicum Announces Update on Clinical Hold of U.S. BPX-501 Studies
HOUSTON, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced it has received notification from the U.S. Food and Drug Administration (FDA)...
Feb 21, 2018 07:00 am ET
Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors
HOUSTON, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Edmund Harrigan, M.D. to its Board of Directors....
Feb 20, 2018 02:50 pm ET
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Bellicum Pharmaceuticals, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Texas on behalf of purchasers of Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”) securities during the period between May 8, 2017 and January 30, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 9, 2018 to seek appointment as lead plaintiff.
Feb 17, 2018 07:00 am ET
Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM
NEW YORK, Feb. 17, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ: BLCM) and certain of its officers.   The class action, filed in United States District Court, for the Southern District of Texas, and docketed under 18-cv-00338, is on behalf of a class consisting of investors who purchased or otherwise acquired Bellicum securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.
Feb 15, 2018 04:12 pm ET
BLCM LOSS NOTICE: Rosen Law Firm Reminds Bellicum Pharmaceuticals, Inc. Investors of Important Deadline in Class Action – BLCM
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) from May 8, 2017 through January 30, 2018, inclusive (the “Class Period”) of the important April 9, 2018 lead plaintiff deadline. The lawsuit seeks to recover damages for Bellicum investors under the federal securities laws.
Feb 13, 2018 10:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline – April 9, 2018
NEW YORK, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ: BLCM) and certain...
Feb 12, 2018 03:17 pm ET
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.
OKLAHOMA CITY, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Federman & Sherwood announces that on February 6, 2018, a class action lawsuit was filed in the United States District Court for the Southern District of Texas against Bellicum Pharmaceuticals,...
Feb 09, 2018 12:36 pm ET
Robbins Arroyo LLP: Bellicum Pharmaceuticals, Inc. (BLCM) Misled Shareholders According to a Recently Filed Class Action
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Bellicum Pharmaceuticals, Inc. (NasdaqGM: BLCM). The complaint is brought on behalf of all purchasers of Bellicum securities between May 8, 2017 and January 30, 2018, for alleged violations of the Securities Exc
Feb 08, 2018 01:31 pm ET
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) T
STEVENSON, Md., Feb. 08, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District...
Feb 07, 2018 07:00 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bellicum Pharmaceuticals, Inc. (BLCM)
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM) in the United States District Court for the...
Feb 07, 2018 09:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline - April 9, 2018
NEW YORK, Feb. 7, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ: BLCM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Bellicum securities between May 8, 2017, and January 30, 2018, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/blcm.
Feb 06, 2018 03:13 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. – BLCM
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) from May 8, 2017 through January 30, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Bellicum investors under the federal securities laws.
Feb 06, 2018 01:53 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers – BLCM
NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM) and certain of its officers.   The class action, filed in...
Feb 06, 2018 01:52 pm ET
BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, Feb. 6, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ: BLCM).
Feb 05, 2018 07:00 am ET
Bellicum Pharmaceuticals Appoints Dr. William Grossman as Chief Medical Officer
HOUSTON, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of William Grossman, M.D., Ph.D., as Chief Medical Officer,...
Jan 31, 2018 12:26 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bellicum Pharmaceuticals, Inc. (BLCM)
NEW YORK, Jan. 31, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ: BLCM). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/blcm.
Jan 31, 2018 11:41 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bellicum Pharmaceuticals, Inc. - BLCM
NEW YORK, Jan. 31, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ: BLCM).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Jan 30, 2018 04:47 pm ET
Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States
HOUSTON, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company has received notice from the U.S. Food and...
Dec 11, 2017 10:00 am ET
Bellicum Pharmaceuticals Announces Presentations of its Controllable Switch Technology Platform at the American Society of Hematology 2017 Annual Meeting
Results support technology’s potential to control activation, persistence, and elimination of cell therapies for improved safety and efficacy
Dec 09, 2017 02:00 pm ET
Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases
112 pediatric patients with a median follow-up of 18 months were reviewed in an oral presentation at the 59th Annual Meeting of the American Society of Hematology
Nov 08, 2017 07:00 am ET
Bellicum Pharmaceuticals to Present at the Jefferies 2017 London Healthcare Conference
HOUSTON, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15 at 9:20 a.m. GMT in London, UK....
Nov 08, 2017 07:00 am ET
Bellicum Pharmaceuticals to Present at the Jefferies 2017 London Healthcare Conference
HOUSTON, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2017...
Nov 07, 2017 04:05 pm ET
Bellicum Reports Third Quarter 2017 Financial Results
HOUSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the third quarter ended September 30, 2017, and provided an update on recent developments....
Nov 07, 2017 04:05 pm ET
Bellicum Reports Third Quarter 2017 Financial Results
HOUSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the third quarter ended September 30, 2017, and provided...
May 18, 2017 07:00 am ET
Bellicum Announces Clinical Presentations at the 22nd Congress of the European Hematology Association
Overall-cohort abstract on BPX-501 selected for presentation at Presidential Symposium...
May 15, 2017 04:30 pm ET
Bellicum Pharmaceuticals Announces Management Changes
HOUSTON, May 15, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Annemarie Moseley, Ph.D., M.D., the Company’s Chief Operating Officer and Executive Vice President of Clinical Development, has announced her intention to leave the organization, effective July 31, 2017. Dr. Moseley will transition her responsibilities over this period and will remain a consultant to Bellicum through January 2019. The Company has initiated a search for...
May 08, 2017 04:05 pm ET
Bellicum Pharmaceuticals Reports First Quarter 2017 Financial Results
HOUSTON, May 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter ended March 31, 2017 and provided an update on recent developments....
Mar 23, 2017 06:20 pm ET
Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
HOUSTON, March 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $12.00 per share. The aggregate offering size, before deducting the underwriting discounts and commissions and other offering expenses, is expected to be approximately $60.0 million. The offering is expected to close on or about March 29, 2017, subject to customary closing conditions. In addition, the underwriters have been granted a 30-day option to purchase up to an addit...
Mar 22, 2017 04:01 pm ET
Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
HOUSTON, March 22, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. Bellicum expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. All shares of common stock to be sold in the offering will be offered by Bellicum. The offering is subject to market and other conditions, and there can be no assurance as to ...
Mar 13, 2017 04:05 pm ET
Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
On track to complete enrollment in E.U. registration trials for BPX-501 and rimiducid this year...
Feb 22, 2017 04:15 pm ET
Bellicum Presents Updated Clinical Results at 2017 BMT Tandem Meetings on BPX-501 in Orphan Inherited Blood Disorders and Hematologic Cancers
HOUSTON, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the presentation of updated clinical results from its multicenter BP-004 clinical trial of BPX-501 and rimiducid at the 2017 BMT Tandem Meetings. Results on 73 patients with more than six months of follow-up demonstrated that the use of BPX-501 following an alpha/beta-depleted, haploidentical hematopoietic stem cell transplant (haplo-HSCT) resulted in rapid immune recove...
Feb 21, 2017 07:00 am ET
Bellicum Announces Initiation of Patient Dosing with Controllable CAR T-Cell Product Candidate
HOUSTON, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced it has dosed the first patient with BPX-601, the first CAR T-cell product candidate to enter clinical studies that is designed to enable control over the expansion and stimulation of the cells. BPX-601 targets solid tumors that express PSCA (prostate stem cell antigen), with an initial indication in non-resectable pancreatic cancer....
Jan 31, 2017 07:00 am ET
Bellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of Growth
Rick FairHOUSTON, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Rick Fair as President and Chief Executive Officer, and as a member of the Board of Directors, effective immediately. Mr. Fair joins Bellicum from Genentech/Roche, where he was Senior Vice President, Head of Oncology Global Product Strategy, and brings an impressive record of results in global, strat...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.